GlassScriptPhysician profile
Jesse Galvez Martinez
NPI 1699762567
$2,031.15
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $426 · 2021: $18.91 · 2024: $1,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,225.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $673.46 | 2019-2024 | Farxiga |
| Aimmune Therapeutics, INC. | $261.39 | 2024 | |
| Amgen INC. | $257.58 | 2024 | Otezla, Repatha, Evenity |
| Otsuka America Pharmaceutical, INC. | $232.97 | 2024 | Rexulti |
| Pfizer INC. | $154.26 | 2019-2024 | |
| Glaxosmithkline, LLC. | $107.91 | 2024 | Arexvy |
| Lilly USA, LLC | $90.77 | 2024 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $43.54 | 2024 | |
| Indivior INC. | $33.31 | 2024 | Sublocade |
| Astellas Pharma US INC | $25.90 | 2024 | Veozah |
| Melinta Therapeutics, LLC | $25.46 | 2024 | Rezzayo, Kimyrsa |
| Esperion Therapeutics, INC. | $23.50 | 2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.57 | 2024 | Jardiance |
| Genentech USA, INC. | $18.91 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.19 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $14.64 | 2024 | Ozempic, Rybelsus |
| Circassia INC. | $14.36 | 2020 | |
| Exact Sciences Corporation | $13.43 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.